Active trials, both recruiting and not recruiting, testing targets not aforementioned (IDH, FGFR, PARP, HER2, ALK, ROS, and the MAPK pathway)

NCT Phase Status Tumors Line of treatment Target Experimental treatment Standard treatment Primary endpoints Sponsor
NCT04491942 1 Recruiting CCA UNK ATR* Cis + BAY 1895344 +/– Gem N.A. AEs, RP2D No-profit
NCT03829436 1 Recruiting CCA NTA PPAR-alfa* TPST-1120 +/– nivolumab N.A. DLT, AEs, MTD Profit
NCT04430842 1 Recruiting CCA NTA LAT1 QBS10072S N.A. MTD Profit
NCT04152018 1 Recruiting eCCA UNK Integrin alpha-V/beta-8* PF 06940434 +/– IT N.A. DLT, AEs, ORR, PFS, DOR Profit
NCT03422679 1/2 Recruiting CCA NTA NOTCH* CB-103 N.A. DLT, ORR Profit
NCT03907852 1/2 Recruiting CCA ≥ 2 L Protein mesothelin Gavo-cel N.A. 3 months ORR Profit
NCT04068194 1/2 Recruiting CCA and gallbladder cancer NTA DNA activated protein kinase (DNA-PK)* Nedisertib N.A. MTD, ORR Profit
NCT03633773 1/2 Recruiting iCCA 1 L Glycosylated Mucin1 MUC-1 CART cell IT N.A. DCR No-profit
NCT03768375 2 Recruiting eCCA, gallbladder cancer 1 L Precision target therapy based on tumor molecular profiling FORFIRINOX or cetuximab or trastuzumab or gefitinib or lapatinib or everolimus or sorafenib or crizotinib FOLFIRINOX PFS No-profit
NCT03801915 2 Recruiting CCA Perioperative CA 19-9 epitope MVT-5873 N.A. 1-year recurrence rates, safety Profit
NCT04034238 2 Recruiting eCCA 2 L Protein mesothelin LMB-100 + tofacitinib N.A. Safety, timing of anticorpal response Profit
NCT04383210 2 Recruiting CCA and gallbladder cancer NTA NRG1 gene fusion Seribantumab N.A. ORR Profit
NCT03102320 1b Completed CCA UNK Protein mesothelin Anetumab ravtansine + chemotherapy N.A. MTD, ORR, DOR Profit
NCT00101972 1 Completed CCA and gallbladder cancer 2–4 L Glycotope RAAG12* RAV12 N.A. Toxicity by CTCAE Profit
NCT00020579 1 Completed CCA and gallbladder cancer NTA Histone deacetylase* Entinostat N.A. DLT, MTD, pharmaco-kinetics No-profit
NCT00027534 1 Completed Gallbladder cancer Received prior therapy with possible survival benefit or refused such therapy CEA TRICOM-CEA(6D) N.A. Safety and feasibility No-profit
NCT02836847 2 UNK eCCA and gallbladder cancer 1 L Precision target therapy based on tumor molecular profiling GEMOX + cetuximab or trastuzumab or gefitinib or lapatinib or everolimus or sorafenib or crizotinib GEMOX PFS No-profit
NCT04895046 2 Not yet recruiting CCA Maintenance Defined HRD signature Niraparib and dostarlimab N.A, PFS Profit
NCT04801095 1 Recruiting CCA 1 L pTyr-mtRTK WM-S1-030 N.A. MTD Profit
NCT05001282 1/2 Not yet recruiting CCA NTA FRα over-expressing ELU001 N.A. MTD/RP2D Profit

We reported four trials defined as “completed” on www.clinicaltrials.gov, whose results have never been published. Were excluded a “terminate” trial, that is a study stopped early, whose participants are no longer being examined or treated (NCT00012246), and two “withdrawn” trials, stopped early, before enrolling their first participants (NCT01501604 and NCT01859182). *Not inclusion criteria; ATR: ataxia-telangiectasia mutated (ATM) and RAD3-related; LAT: large amino acid transporter; FOLFIRINOX: leucovorin calcium, fluorouracil, irinotecan hydrochloride and oxaliplatin; CA: carbohydrate antigen; NRG1: neuroregulin1; CTCAE: common terminology criteria for adverse events; CEA: carcinoembryonic antigen; HRD: homologous recombination deficency; RTK: receptor tyrosine kinases; FRα: folate receptor alpha